Catalyst Dossier · compiled by CeliA 🧫

Grifols SA (GRFS)

Pharmaceutical Preparations · market cap $5.0B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-27

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Grifols S.A. (GRFS) is a Barcelona-founded, 117-year-old global plasma-derived medicines company with ~23,800 employees serving 110+ countries. The company operates a broad pipeline of plasma-derived and biologics assets spanning hemostasis, immunodeficiency, alpha-1 antitrypsin deficiency (AATD), albumin therapeutics, and surgical bleeding, with the most immediate Phase 3 catalyst being Alpha-1 MP data expected around August 15, 2026. At ~$7.39/share and a ~$4.96B market cap, GRFS trades well below analyst consensus targets of ~$10.87.

The catalyst path

2026-07-27Earningsimp 5/10
2026-08-15 (est.)Phase 3 · Alpha-1 MPimp 9/10

Pipeline

Asset	Phase	Indication
FS Grifols	Phase 3	Target Bleeding Site During Peripheral Vascular Surgery
Liquid Alpha₁-PI	Phase 3	Alpha₁-Antitrypsin Deficiency
Immune Globulin Intravenous (Human)	Phase 2	Immunologic Deficiency Syndrome
Convalescent anti-SARS-CoV-2 MBT Plasma	Phase 2	COVID-19
Prolastin-C, 60 mg/kg	Phase 2	Emphysema
GRF312 5%	Phase 2	Dry Eye Disease
Prolastin	Phase 2	COVID-19
Human thrombin	Phase 2	Hemostasis
Alpha-1 MP	Phase 3	Alpha 1-Antitrypsin Deficiency
Albutein 20%	Phase 3	Decompensated Cirrhosis and Ascites
BeneFIX	Phase 2	Hemophilia B
Albumin (Human) 20%, United States Pharmacopeia (USP)	Phase 2	Alpha 1-Antitrypsin Deficiency
alpha-1 proteinase inhibitor (human)	Phase 3	Alpha 1-Antitrypsin Deficiency
Fibrin Sealant (FS) Grifols	Phase 3	Soft Tissue Surgical Bleeding
IVIG-PEG	Phase 3	Primary Immunodeficiency
Intravenous Immune Globulin	Phase 2	COVID-19
Albumin	Phase 2	Amyotrophic Lateral Sclerosis
Fibrin Sealant Grifols	Phase 3	Excessive Bleeding During Surgery
Specific intravenous anti-hepatitis B immunoglobulin	Phase 3	Hepatitis B, Chronic
IGIV3I Grifols	Phase 3	Immune (Idiopathic) Thrombocytopenic Purpura

Price & technical context

3-month

-11.7%

6-month

-22.4%

12-month

-21.7%

52-wk range

$7.08–$10.85

vs 50-day MA

-8.8%

vs 200-day MA

-18.4%

Realized vol

31.4%

Max drawdown

-34.7%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GRFS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.